The Phase III trial of clostridial collagenase for residual stage Dupuytren's disease aims to establish its safety and efficacy compared to placebo. Given the prevalence of Dupuytren's disease and the limited treatment options available, successful outcomes could position this therapy favorably in a niche market. The trial's completion in April 2004 suggests a potential for market entry, contingent on regulatory approval. Competitive landscape analysis should focus on existing treatments, including surgical options and emerging therapies, to assess market positioning and pricing strategies. Diligence should include an evaluation of reimbursement pathways and potential partnerships for commercialization.